Investors have once again turned to Chinese pharmaceutical company Jiangsu Hengrui to create a new biotech startup, this time to advance a new medicine for heart disease.

The new venture, Braveheart Bio, was built around a single drug: a small molecule medicine for hypertrophic cardiomyopathy . The condition causes the walls of the heart chamber to thicken and become stiff, winnowing the amount of blood that can be pumped through. It affects about one in every 500 adults in the U.S.

That single drug candidate was enough to excite investors like Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences. They’ve given Braveheart $185 million to run a global late-stage clinical trial next year.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page